Patents Assigned to Volastra Therapeutics, Inc.
-
Publication number: 20240428939Abstract: The present application provides methods and systems for detecting and quantifying chromosomal instability from histology images with machine-learning. Also described herein are methods for selecting treatments for a medical disease, by determining a chromosomal instability metric from histology images. The disclosed methods and systems may also be used to investigate disease progression and prognosis.Type: ApplicationFiled: September 21, 2022Publication date: December 26, 2024Applicant: Volastra Therapeutics, Inc.Inventors: Akanksha VERMA, Christina ENG, Sarah BETTIGOLE, Rahul GOPALKRISHNAN, Kristen SEVERSON, Nicolo FUSI, Philip ROSENFIELD, Zongliang JI, Aliasghar MORTAZI
-
Publication number: 20240376113Abstract: The present disclosure relates generally to inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), compositions thereof, and methods of using said compounds and compositions thereof. More specifically, the present disclosure relates to triazolopyrimidine and imidazolopyrimidine inhibitors of ENPP1 and methods of their use for treating disease mediated by ENPP1.Type: ApplicationFiled: July 12, 2024Publication date: November 14, 2024Applicant: Volastra Therapeutics, Inc.Inventors: Sarah BETTIGOLE, Michael SU, Derek A. COGAN, Leon VAN BERKOM, Piotr NIECZYPOR, Gydo VAN DER HEIJDEN, Prashanna VIJAYACHANDRAN
-
Publication number: 20240351984Abstract: The present disclosure relates generally to inhibitors of KIF18A, compositions thereof, and methods of using said compounds and compositions thereof. More specifically, the present disclosure relates to indoline inhibitors of KIF18A and methods of their use for treating disease mediated by KIF18A, such as cancer.Type: ApplicationFiled: June 5, 2024Publication date: October 24, 2024Applicant: Volastra Therapeutics, Inc.Inventor: Derek A. COGAN
-
Patent number: 12091412Abstract: The present disclosure relates generally to inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), compositions thereof, and methods of using said compounds and compositions thereof. More specifically, the present disclosure relates to triazolopyrimidine and imidazolopyrimidine inhibitors of ENPP1 and methods of their use for treating disease mediated by ENPP1.Type: GrantFiled: June 15, 2021Date of Patent: September 17, 2024Assignee: Volastra Therapeutics, Inc.Inventors: Sarah Bettigole, Michael Su, Derek A. Cogan, Leon Van Berkom, Piotr Nieczypor, Gydo Van Der Heijden, Prashanna Vijayachandran
-
Patent number: 12084420Abstract: The present disclosure relates generally to inhibitors of KIF18A, compositions thereof, and methods of using the compounds and compositions thereof. More specifically, the present disclosure relates to indoline inhibitors of KIF18A and methods of their use for treating disease mediated by KIF18A, such as cancer.Type: GrantFiled: August 25, 2022Date of Patent: September 10, 2024Assignee: Volastra Therapeutics, Inc.Inventor: Derek A. Cogan
-
Publication number: 20230382889Abstract: The present disclosure relates generally to inhibitors of KIF18A, compositions thereof, and methods of using said compounds and compositions thereof. More specifically, the present disclosure relates to inhibitors of KIF18A and methods of their use for treating disease mediated by KIF18A, such as cancer.Type: ApplicationFiled: April 27, 2023Publication date: November 30, 2023Applicant: Volastra Therapeutics, Inc.Inventor: Derek A. COGAN
-
Patent number: 11780849Abstract: The present disclosure relates generally to inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), compositions thereof, and methods of using said compounds and compositions thereof. More specifically, the present disclosure relates to sulfoximine-based inhibitors of ENPP1 and methods of their use for treating disease mediated by ENPP1.Type: GrantFiled: May 3, 2021Date of Patent: October 10, 2023Assignee: Volastra Therapeutics, Inc.Inventors: Derek A. Cogan, Sarah Bettigole, Leon Van Berkom, Piotr Nieczypor, Michael Su, Rutger Folmer
-
Publication number: 20230147507Abstract: The present disclosure relates generally to inhibitors of KIF18A, compositions thereof, and methods of using said compounds and compositions thereof. More specifically, the present disclosure relates to indoline inhibitors of KIF18A and methods of their use for treating disease mediated by KIF18A, such as cancer.Type: ApplicationFiled: August 25, 2022Publication date: May 11, 2023Applicant: Volastra Therapeutics, Inc.Inventor: Derek A. COGAN
-
Publication number: 20230117405Abstract: The present application provides methods and systems for detecting and quantifying chromosomal instability from histology images with machine learning. Also described herein are methods for selecting treatments for a medical disease, by determining a chromosomal instability pathological metric from histology images. The disclosed methods and systems may also be used to investigate disease progression and prognosis.Type: ApplicationFiled: September 21, 2022Publication date: April 20, 2023Applicants: Volastra Therapeutics, Inc., Center for Technology Licensing at Cornell University (CTL)Inventors: Akanksha VERMA, Olivier ELEMENTO, Zhuoran XU
-
Publication number: 20230036933Abstract: The present disclosure relates generally to inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), compositions thereof, and methods of using said compounds and compositions thereof. More specifically, the present disclosure relates to triazolopyrimidine and imidazolopyrimidine inhibitors of ENPP1 and methods of their use for treating disease mediated by ENPP1.Type: ApplicationFiled: June 15, 2021Publication date: February 2, 2023Applicant: Volastra Therapeutics, Inc.Inventors: Sarah BETTIGOLE, Michael SU, Derek A. COGAN, Leon VAN BERKOM, Piotr NIECZYPOR, Gydo VAN DER HEIJDEN, Prashanna VIJAYACHANDRAN
-
Publication number: 20230002406Abstract: The present disclosure relates generally to inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), compositions thereof, and methods of using said compounds and compositions thereof. More specifically, the present disclosure relates to sulfoximine-based inhibitors of ENPP1 and methods of their use for treating disease mediated by ENPP1.Type: ApplicationFiled: May 3, 2021Publication date: January 5, 2023Applicant: Volastra Therapeutics, Inc.Inventors: Derek A. COGAN, Sarah BETTIGOLE, Leon VAN BERKOM, Piotr NIECZYPOR, Michael SU, Rutger FOLMER
